pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
argenx is a pharma organization headquartered in GENT, BE. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bullous Pemphigoid, Thyroid Eye
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
ARGX-119-2303
Phase 2 · small molecule · Amyotrophic Lateral Sclerosis (ALS)
ARGX-119-2303 for Amyotrophic Lateral Sclerosis (ALS) is a Phase 2 program (small_molecule) at argenx with 1 ClinicalTrials.gov record(s).
Internal code ARGX-119-2303
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- argenx
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Amyotrophic Lateral Sclerosis (ALS)
- Status
- active
- Trials
- 1